CRVS stock forecast
Our latest prediction for Corvus Pharmaceuticals Inc's stock price was made on the March 31, 2022 when the stock price was at 1.64$.
In the short term (2weeks), CRVS's stock price should outperform the market by 4.44%. During that period the price should oscillate between -10.36% and +19.01%.
In the medium term (3months), CRVS's stock price should outperform the market by 3.21%. During that period the price should oscillate between -38.72% and +51.84%.Get email alerts
Create a solid portfolio with CRVS
About Corvus Pharmaceuticals Inc
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company. Corvus' lead product candidate is CPI-006, a humanized monoclonal antibody directed against CD73 that has exhibited immunomodulatory activity and activation of immune cells in preclinical studies. CPI-006 is being evaluated in a Phase 3 clinical trial for the treatment of hospitalized patients with COVID-19 and in a multicenter Phase 1/1b oncology clinical trial as a single agent, in combination with ciforadenant and pembrolizumab. The Company's second clinical program, CPI-818, is an investigational, oral, small molecule drug that selectively inhibited ITK in preclinical studies, and is in a multicenter Phase 1/1b clinical trial in patients with several types of T-cell lymphomas. Its third clinical program, ciforadenant (CPI-444), is an oral, small molecule inhibitor of the A2A receptor.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -1.03$ per share.
The book value per share is 4.36$
Three months stock forecastMarch 31, 2022
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|